IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 176-200 out of 1365.

<< < 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 > >>

Public Release: 6-Jul-2015
Nature Cell Biology
New paradigm for treating 'inflammaging' and cancer
Intermittent dosing with rapamycin breaks the inflammatory loop associated with senescence. Once disrupted, it takes time for the loop to reestablish itself -- providing proof-of-principal that intermittent dosing could provide a way to reap the benefits of rapamycin while bypassing its safety issues. The FDA-approved drug increases healthspan and lifespan in mice. DNA-damaging chemotherapies cause senescence in the tumor microenvironment. In mice, intermittent dosing blocked the inflammation believed to fuel the proliferation of residual cancer cells.
National Institutes of Health, Hillblom Medical Foundation, National Natural Science Foundation of China, Prostate Cancer Foundation

Contact: Kris Rebillot
krebillot@buckinstitute.org
415-209-2080
Buck Institute for Research on Aging

Public Release: 6-Jul-2015
Cancer
Pazopanib improves progression-free survival without impairing HRQOL
Results of EORTC trial 62072 appearing in Cancer show that in patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result.
GlaxoSmithKline

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer

Public Release: 6-Jul-2015
ACS Central Science
Extra DNA acts as a 'spare tire' for our genomes
Carrying around a spare tire is a good thing -- you never know when you'll get a flat. Turns out we're all carrying around 'spare tires' in our genomes, too. Today, in ACS Central Science, researchers report that an extra set of guanines (or 'G's) in our DNA may function just like a 'spare' to help prevent many cancers from developing.

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society

Public Release: 6-Jul-2015
Journal of Cell Biology
Cellular sentinel prevents cell division when the right machinery is not in place
For cell division to be successful, pairs of chromosomes have to line up just right before being swept into their new cells, like the opening of a theater curtain. They accomplish this feat in part thanks to structures called centrioles that provide anchors for the curtain's ropes. Researchers recently learned that most cells will not divide without centrioles, and they found out why: The protein p53 monitors centriole numbers to prevent potentially disastrous cell divisions.
Leukemia Research Foundation, W.W. Smith Charitable Trust, March of Dimes Basil O'Conner Scholar Award, Pew Scholar Award, Kimmel Scholar Award

Contact: Catherine Kolf
ckolf@jhmi.edu
443-287-2251
Johns Hopkins Medicine

Public Release: 6-Jul-2015
JAMA Internal Medicine
Detecting more small cancers in screening mammography suggests overdiagnosis
Screening mammography was associated with increased diagnosis of small cancers in a study across US counties but not with significant changes in breast cancer deaths or a decreased incidence of larger breast cancers, which researchers suggest may be the result of overdiagnosis, according to an article published online by JAMA Internal Medicine.

Contact: Peter Reuell
preuell@fas.harvard.edu
617-496-8070
The JAMA Network Journals

Public Release: 6-Jul-2015
Proceedings of the National Academy of Sciences
Killer sea snail a target for new drugs
University of Queensland pain treatment researchers have discovered thousands of new peptide toxins hidden deep within the venom of just one type of Queensland cone snail. Researchers hope the new molecules will be promising leads for new drugs to treat pain and cancer.
National Health and Medical Research Council

Contact: Gemma Ward
g.ward1@uq.edu.au
61-733-462-155
University of Queensland

Public Release: 5-Jul-2015
PLOS ONE
Arthritis drug could be used to treat blood cancer sufferers
Scientists at the University of Sheffield have discovered that a common drug given to arthritis sufferers could also help to treat patients with blood cancers.
Cancer Research UK, Yorkshire Cancer Research

Contact: Clare Parkin
mediateam@sheffield.ac.uk
01-142-229-852
University of Sheffield

Public Release: 4-Jul-2015
ESMO 17th World Congress on Gastrointestinal Cancer
Annals of Oncology
Second-line cetuximab active beyond progression in quadruple wild-type patients with mCRC
Patients with metastatic colorectal cancer (mCRC) that are mutation-free in the KRAS, NRAS, BRAF and PIK3CA genes showed significant benefit from continuing anti-epidermal growth factor receptor (EGFR) therapy beyond progression following first-line chemotherapy and an anti-EGFR monoclonal antibody, according to study results presented at the ESMO 17th World Congress on Gastrointestinal Cancer in Barcelona, Spain.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 3-Jul-2015
ESMO 17th World Congress on Gastrointestinal Cancer
Annals of Oncology
Studies confirm regorafenib benefit in pre-treated metastatic colorectal cancer
The phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC), researchers announced at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona. The safety profile and progression free survival were similar to phase III trial results.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 2-Jul-2015
Developmental Cell
Hippo dances with hormones
In fruit flies, the abnormal growth induced by Hippo pathway disruption depends on genes involved in responding to the steroid hormone ecdysone. This has potential implications for human biology, since the Hippo pathway is involved in suppressing cancer growth and forming embryonic stem cells.
NIH/National Institute of General Medical Sciences, NIH/National Cancer Institute

Contact: Quinn Eastman
qeastma@emory.edu
404-727-7829
Emory Health Sciences

Public Release: 2-Jul-2015
European Heart Journal
Experts call for 'all hands on deck' to tackle global burden of non-communicable disease
A group of the world's top doctors and scientists working in cardiology and preventive medicine have issued a call to action to tackle the global problem of deaths from non-communicable diseases, such as heart problems, diabetes and cancer, through healthy lifestyle initiatives. Their suggestions to prevent or delay health conditions that cause the deaths of over 36 million people worldwide each year are published simultaneously in Mayo Clinic Proceedings and the European Heart Journal.

Contact: Emma Mason
wordmason@mac.com
European Society of Cardiology

Public Release: 2-Jul-2015
Molecular Cell
Melanoma mutation rewires cell metabolism
A mutation found in most melanomas rewires cancer cells' metabolism, making them dependent on a ketogenesis enzyme. The finding points to possible strategies for countering resistance to existing drugs that target the B-raf V600E mutation, or potential alternatives to those drugs. It may also explain why the V600E mutation in particular is so common in melanomas.
NIH/National Cancer Institute, American Cancer Society, Leukemia and Lymphoma Society

Contact: Judy Fortin
judy.fortin@emory.edu
404-778-4580
Emory Health Sciences

Public Release: 2-Jul-2015
Nature Communications
Scientists advance cancer drug design with image of 1 of key proteins of life
Scientists have pioneered the use of a high-powered imaging technique to picture in exquisite detail one of the central proteins of life -- a cellular recycling unit with a role in many diseases.
Cancer Research UK, Medical Research Council

Contact: Henry French
henry.french@icr.ac.uk
020-715-35582
Institute of Cancer Research

Public Release: 2-Jul-2015
Cell Stem Cell
New measurements reveal differences between stem cells for treating retinal degeneration
By growing two types of stem cells in a '3-D culture' and measuring their ability to produce retinal cells, a team lead by St. Jude Children's Research Hospital researchers has found one cell type to be better at producing retinal cells.
National Institutes of Health, Howard Hughes Medical Institute, Alex's Lemonade Stand Foundation for Childhood Cancer and ALSAC

Contact: Frannie Marmorstein
frannie.marmorstein@stjude.org
901-379-6072
St. Jude Children's Research Hospital

Public Release: 2-Jul-2015
Psycho-Oncology
Cancer survivors who smoke perceive less risk from tobacco
Cancer survivors who smoke report fewer negative opinions about smoking, have more barriers to quitting, and are around other smokers more often than survivors who had quit before or after their diagnosis.
American Cancer Society

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society

Public Release: 1-Jul-2015
ESMO 17th World Congress on Gastrointestinal Cancer
Annals of Oncology
Evaluation of NK1 antagonists for emesis prevention in oxaliplatin chemo: SENRI trial
The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, results of a Japanese study presented today at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona reveal.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 1-Jul-2015
Nature Communications
How removing a protein slows blood vessel growth in tumors
Scientists from the University of Leeds and The Institute of Cancer Research, London, have discovered a new protein which triggers the growth of blood vessels in breast cancer tumors which have spread to the brain, a common location which breast cancer can spread to.

Contact: Ben Jones
B.P.Jones@leeds.ac.uk
44-011-334-38059
University of Leeds

Public Release: 1-Jul-2015
The EMBO Journal
Live imaging reveals how wound healing influences cancer
Researchers in the United Kingdom and Denmark have studied the 'see-through' larvae of zebrafish to reveal how wound healing leads to melanoma.

Contact: Barry Whyte
barry.whyte@embo.org
EMBO

Public Release: 1-Jul-2015
ESMO 17th World Congress on Gastrointestinal Cancer
Annals of Oncology
Patients with lowest BMI have shortest survival in pooled analysis of bev in mCRC
Patients with the lowest body mass index had the shortest overall survival in an analysis of bevacizumab studies in metastatic colorectal cancer presented for the first time at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 1-Jul-2015
Neuro-Oncology: Clinical Practice
Improved survival in adult patients with low-grade brain tumors
Using clinical data collected over the past decade through a US cancer registry, researchers at the University of California, San Diego School of Medicine demonstrated that significant strides have been made in improving the survival of adult patients with low-grade gliomas, a slow-growing yet deadly form of primary brain cancer.
Sontag Foundation, Burroughs Wellcome Foundation, Kimmel Foundation, Doris Duke Foundation, Forbeck Foundation

Contact: Jackie Carr
jcarr@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 1-Jul-2015
ESMO 17th World Congress on Gastrointestinal Cancer
Thin colorectal cancer patients have shorter survival than obese patients
Although being overweight with a high body-mass index has long been associated with a higher risk for colorectal cancer, thinner patients might not fare as well after treatment for advanced cancer, according to a new study from Duke Medicine.
Genentech Inc.

Contact: Samiha Khanna
samiha.khanna@duke.edu
919-419-5069
Duke University Medical Center

Public Release: 1-Jul-2015
PLOS ONE
New drug for neuroblastoma shows promise in phase I study
Researchers at Spectrum Health Helen DeVos Children's Hospital have completed the first clinical trial of a new treatment for children suffering from neuroblastoma. In a clinical trial led by Giselle Sholler, M.D., and the Neuroblastoma and Medulloblastoma Translational Research Consortium, DFMO, an investigational agent, showed minimal side effects with long-term survival of three patients. This is the first clinical study of an oral dosing form of DFMO in any pediatric population.

Contact: Rick Jensen
richard.jensen@spectrumhealth.org
616-391-5291
Spectrum Health

Public Release: 1-Jul-2015
Molecular Cancer Therapeutics
Subcutaneous administration of multispecific antibody improves tumor treatment
Tumor treatment with multispecific antibodies is significantly more tolerable if administered subcutaneously rather than via the bloodstream, which was the standard procedure until now. This was the result of an animal model study undertaken by researchers at Helmholtz Zentrum München in cooperation with the Munich biotech company Trion Research. According to the scientists, the findings published in the journal Molecular Cancer Therapeutics could lead to shorter hospital stays, among other benefits for patients.
Bayerische Forschungsstiftung

Contact: Dr. Ralph Mocikat
Mocikat@helmholtz-muenchen.de
49-893-187-1302
Helmholtz Zentrum München - German Research Center for Environmental Health

Public Release: 1-Jul-2015
Cancer Cell
Experimental drug combined with standard chemo may shrink ovarian cancers
Working in cell cultures and mice, researchers at Johns Hopkins have found that an experimental drug called fostamatinib combined with the chemotherapy drug paclitaxel may overcome ovarian cancer cells' resistance to paclitaxel.
National Institutes of Health, Conquer Cancer Foundation, HERA Women's Cancer Foundation, Ovarian Cancer Research Fund

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 1-Jul-2015
International Journal of Radiation Oncology, Biology and Physics
Many patients with advanced form of larynx cancer not receiving recommended treatment
Despite findings of previous studies and published guidelines, nearly two-thirds of patients with T4a larynx ('voice box') cancer are not receiving a total laryngectomy (surgical removal of the larynx), the recommended form of treatment, and as a result, have significantly worse survival rates versus those treated with a total laryngectomy, a new study published in the International Journal of Radiation Oncology, Biology and Physics by experts at Penn Medicine found.

Contact: Katie Delach
katie.delach@uphs.upenn.edu
215-349-5964
University of Pennsylvania School of Medicine

Showing releases 176-200 out of 1365.

<< < 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 > >>

  Search News Releases

     

 

EurekAlert!